Citius Pharmaceuticals (CTXR) Retained Earnings (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Retained Earnings came in at $329.8 million in Q1 2026, up 248.51% YoY from $94.6 million in Q1 2025, and up 233.5% on a QoQ basis from -$247.0 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Retained Earnings (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Retained Earnings data on file, last reported at $329.8 million in Q1 2026.
- Quarterly Retained Earnings rose 248.51% year-over-year to $329.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $329.8 million (up 248.51% YoY) and the FY2025 annual result came in at -$238.8 million, down 187.98% from the prior year.
- Retained Earnings improved to $329.8 million in Q1 2026, from -$247.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $329.8 million in Q1 2026 to a low of -$247.0 million in Q4 2025.
- A 5-year average of $77.9 million and a median of $232.4 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 281.29% — and 2025, when it sank 189.33%.
- Tracing CTXR's Retained Earnings over 5 years: stood at $233.6 million in 2022, then tumbled by 173.41% to -$171.5 million in 2023, then soared by 261.28% to $276.5 million in 2024, then slumped by 189.33% to -$247.0 million in 2025, then soared by 233.5% to $329.8 million in 2026.
- The last three Retained Earnings figures came in at $329.8 million (Q1 2026), -$247.0 million (Q4 2025), and -$238.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 343.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.78 Mn |
| Dec 31, 2025 | -247.02 Mn |
| Sep 30, 2025 | -238.80 Mn |
| Jun 30, 2025 | 295.89 Mn |
| Mar 31, 2025 | -222.05 Mn |
| Dec 31, 2024 | 276.54 Mn |
| Sep 30, 2024 | 271.44 Mn |
| Jun 30, 2024 | 276.08 Mn |
| Mar 31, 2024 | 259.21 Mn |
| Dec 31, 2023 | -171.46 Mn |
| Sep 30, 2023 | -162.23 Mn |
| Jun 30, 2023 | -152.29 Mn |
| Mar 31, 2023 | 234.87 Mn |
| Dec 31, 2022 | 233.57 Mn |
| Sep 30, 2022 | 232.37 Mn |
| Jun 30, 2022 | -121.70 Mn |
| Mar 31, 2022 | 230.28 Mn |
| Dec 31, 2021 | 229.08 Mn |
| Sep 30, 2021 | 228.08 Mn |
| Jun 30, 2021 | -91.09 Mn |